Accelerating Anticancer Agent Development and Validation Workshop (AAADV)

Goals and Objectives:

1. To expedite the development and validation processes for new anticancer and cancer prevention agents.
2. To educate investigators, so new agents may be made available to patients at a more efficient rate more rapidly in the future.
3. To improve understanding of cancer drug development strategies to lead to a series of pivotal clinical trials demonstrating efficacy and patient benefit.

Who Should Attend:

• Industry: Registrants should be involved in drug development.
• Government: Registrants should be employed by an U.S. government agency and be involved in oncology drug discovery or development.
• Academic: Registrants should be employed by a recognized academic institution and be involved or have an interest in oncology drug discovery and/or development. Previous or current experience in the conduct of clinical trials is helpful, but not required.
• Advocates: Consumer and/or patient advocates should be sponsored by a nationally recognized advocacy organization or foundation. Advocates should have a background in clinical trial design and the role of the advocate in the development process.

Contact

If to Duke:

• Mary Ruemker
  DUMC Box 2606
  Durham, North Carolina 27710
  mary.ruemker@duke.edu

If to FDA:

• Jura Viesulas, MS, EdD
  Office of Hematology and Oncology Products
  Bldg. 22 Room 2200
  10903 New Hampshire Avenue
  Food and Drug Administration
  Silver Spring, MD 20993
  jura.viesulas@fda.hhs.gov